In our study, the RANKL inhibitor denosumab, used in conjunction with CDK4/6 inhibitors, was observed to delay SREs following bone metastasis and have a lower SRE incidence compared to zoledronic acid; this result suggests a clinical manifestation of the aforementioned mechanisms. The gene discussed is TNFSF11; the disease is bone metastasis.